title: Evaluation of the radiation pneumonia development risk in lung cancer cases.
abstract: BACKGROUND
  Concurrent chemo-radiotherapy is the recommended standard treatment modality for patients with locally advanced lung cancer. The purpose of three-dimensional conformal radiotherapy (3DCRT) is to minimize normal tissue damage while a high dose can be delivered to the tumor. The most common dose limiting side effect of thoracic RT is radiation pneumonia (RP). In this study we evaluated the relationship between dose-volume histogram parameters and radiation pneumonitis. This study targeted prediction of the possible development of RP and evaluation of the relationship between dose-volume histogram (DVH) parameters and RP in patients undergoing 3DCRT.
  
  
  METHODS
  DVHs of 41 lung cancer patients treated with 3DCRT were evaluated with respect to the development of grade ≥ 2 RP by excluding gross tumor volume (GTV) and planned target volume (PTV) from total (TL) and ipsilateral (IPSI) lung volume.
  
  
  RESULTS
  Were admitted statistically significant for p<0.05.
  
  
  CONCLUSIONS
  The cut-off values for V5, V13, V20, V30, V45 and the mean dose of TL-GTV; and V13, V20,V30 and the mean dose of TL-PTV were statistically significant for the development of Grade ≥ 2 RP. No statistically significant results related to the development of Grade ≥ 2 RP were observed for the ipsilateral lung and the evaluation of PTV volume. A controlled and careful evaluation of the dose-volume histograms is important to assess Grade ≥ 2 RP development of the lung cancer patients treated with concurrent chemo-radiotherapy. In the light of the obtained data it can be said that RP development may be avoided by the proper analysis of the dose volume histograms and the application of optimal treatment plans.
authors.affiliation: Department of Radiation Oncology, Diyarbakir State Hospital, Diyarbakir, Turkey E-mail : yaseminadas@gmail.com.
authors.forename: Sercan
authors.initials: S
authors.lastname: Yilmaz
authors.forename: Yasemin Guzle
authors.initials: YG
authors.lastname: Adas
authors.forename: Ayse
authors.initials: A
authors.lastname: Hicsonmez
authors.forename: Meltem Nalca
authors.initials: MN
authors.lastname: Andrieu
authors.forename: Serap
authors.initials: S
authors.lastname: Akyurek
authors.forename: Saban Cakir
authors.initials: SC
authors.lastname: Gokce
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy; D015331:Cohort Studies; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017564:Radiation Pneumonitis / Q000209:etiology*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000009:adverse effects*; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents